Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (521-530 of 627) with videos related to

Pageof 63
Sort By:
Blood Cells, Molecules & Diseases|July 30, 2018
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trialPierluigi Tricoci, Megan Neely, Michael J Whitley, et al.
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
The American Journal of Cardiology|August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
American Heart Journal|January 29, 2022
The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study designTina Baykaner, Krishna Pundi, Bryant Lin, et al.
European Heart Journal|February 27, 2004
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromesM T Roe, K W Mahaffey, R Kilaru, et al.
American Heart Journal|August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
Heart (British Cardiac Society)|August 10, 2017
Disease understanding in patients newly diagnosed with atrial fibrillationBrystana G Kaufman, Sunghee Kim, Karen Pieper, et al.
Pageof 63

Showing results (521-530 of 627) with videos related to

Sort By:
Pageof 63
Blood Cells, Molecules & Diseases|July 30, 2018
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trialPierluigi Tricoci, Megan Neely, Michael J Whitley, et al.
European Heart Journal|August 23, 2021
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trialBrendon L Neuen, Megumi Oshima, Vlado Perkovic, et al.
The American Journal of Cardiology|August 23, 2020
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF)Malini Madhavan, DaJuanicia N Holmes, Jonathan P Piccini, et al.
American Heart Journal|January 29, 2022
The ENHANCE-AF clinical trial to evaluate an atrial fibrillation shared decision-making pathway: Rationale and study designTina Baykaner, Krishna Pundi, Bryant Lin, et al.
European Heart Journal|February 27, 2004
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromesM T Roe, K W Mahaffey, R Kilaru, et al.
American Heart Journal|August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
American Heart Journal|December 28, 2020
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trialAshish Sarraju, JingWei Li, Christopher P Cannon, et al.
Kidney International|December 14, 2020
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practiceMegumi Oshima, Meg J Jardine, Rajiv Agarwal, et al.
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
Heart (British Cardiac Society)|August 10, 2017
Disease understanding in patients newly diagnosed with atrial fibrillationBrystana G Kaufman, Sunghee Kim, Karen Pieper, et al.
Pageof 63